Brain tumors comprise a diverse group of neoplasms. Despite the fact that brain tumors only comprise 2 percent of all cancers, they lead to a disproportionate morbidity and mortality rate (
1). Historically, in the past decades, many imaging modalities have been invented to differentiate brain tumors from other mass lesions (
2,
3). The differential diagnoses usually have different nature, prognosis and treatment. Moreover, the differential diagnoses grow wider and more diverse when they have central cystic or necrotic portions, such as abcess, resolving hematoma, radiation necrosis and masses with developmental origin (
4,
5). It is shown that conventional MRI has only 61.4% sensitivity in differentiating brain cystic neoplasms from abcess as their main differential diagnosis (
6). Newer imaging methods such as diffusion weighted imaging (DWI) and proton magnetic resonance spectroscopy (MRS) were shown to light the blind spots of conventional MRI with significant increase in diagnostic accuracy (
5,
6) when used as an adjunct. MRS is a non-invasive diagnostic technique which can determine the concentration of specific metabolites in a pre-selected volume of tissue. These modalities have been widely used to assess the pathophysiology of different neurological abnormalities, e.g. epilepsy (
7) and Parkinson’s disease (
8). In recent years, MRS is finding a role in practice, as a promising diagnostic technique in detecting various neurological and neurosurgical disorders, including focal brain lesions (
9). It is now widely accepted that MRS can distinguish tumors and non-neoplastic lesions based on the Choline (Cho) to Creatinine (Cr) ratio (
10). Further, some studies showed the correlation between the tumor grade and Cho/Cr or Cho to N-Acetyl Aspartate (NAA) values (
11-
14) and some articles discussed differentiation of primary infiltrating from metastatic tumors by increased Cho/Cr ratios at peritumoral regions (
14), although there is no global consensus on both issues yet. In addition, it has been shown that the enhancing rim area which includes infiltrating tumor cells in glioblastoma multiform or inflammatory cells in pyogenic abcess is useful in distinguishing the lesions (
15). However, the possible effectiveness of determining metabolite concentration at the center of the brain lesions with cystic components and its comparison with the rim area remains unknown. This issue shows its worth when a radiologist is faced with several voxels in a multivoxel MRS, some covering the central cystic components and some covering the peripheral regions. Then it is vital to know which voxels are considered more important and weigh more. Some previous studies used peripheral enhancing rim as the preferred site of sampling, while others used the central parts (
5,
6,
16). Whilst peripheral enhancing rim sounds to be the viable portion of the tumor with a greater cellular turnover rate, peripheral voxels are more susceptible to signal contamination from the adjacent normal tissue, a fact that can reduce the accuracy of these voxels. Another fact which should be considered is that MRS acquisition at 1.5 tesla MRI units with short time of echo (TE) protocols are not as accurate as long TE ones, if NAA, Cho or Cr are addressed (
17). However, there is paucity of data focusing on this issue in 3 tesla imagers, especially in clinical practice.